Author:
Heuvel-Eibrink M. M. V. D.,Wiemer E. A. C.,De Boevere M. J.,Van der Holt B.,Vossebeld P. J. M.,Pieters R.,Sonneveld P.
Publisher
Springer Berlin Heidelberg
Reference49 articles.
1. Campos L, Guyotat D, Archimbaud E, CalmardOriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis [see comments]. Blood 1992;79(2):473–476.
2. Del Poeta G, Stasi R, Venditti A, Suppo G, Aronica G, Bruno A, Masi M, Tabilio A, Papa G. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994;8(3):388–394.
3. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S, Papa G. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996;87(5):1997–2004.
4. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89(9):3323–3329.
5. Van den Heuvel-Eibrink MM, van der Holt B, to Boekhorst PA, Pieters R, Schoester M, Lowenberg B, Sonneveld P MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia. Br J Haematol 1997;99(1):76–83.